CD4 and myeloid sarcoma: Up-regulation of miR-223 in CD4+ T-cells fromthe relapsing phase of MS agreed with previousstudies which showed increased expression ofmiR-223 in active brain lesions, PBMCs, andTreg cells of MS patients (27,38).